Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets (Narrative) (Details)

v3.24.1.1.u2
Intangible Assets (Narrative) (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Feb. 25, 2024
Aug. 14, 2023
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Jun. 30, 2023
Aug. 23, 2021
Finite-Lived Intangible Assets [Line Items]                
Impairment of intangible assets           $ 565,000    
Sale proceeds for intangible assets $ 1,000,000   $ 1,000,000.0   $ 1,000,000 0    
Additional contingent cash payments $ 52,500,000              
Amortization of Intangible Assets     $ 5,000 $ 5,000 $ 15,000 $ 121,000    
Patents and Licenses                
Finite-Lived Intangible Assets [Line Items]                
Impairment of intangible assets   $ 25,000         $ 565,000  
RubrYc Therapeutics Inc | Immune-Oncology Antibodies (RTX-003)                
Finite-Lived Intangible Assets [Line Items]                
Investment               $ 7,500,000